1 / 21

Keith A A Fox

CURE and PCI-CURE. Keith A A Fox. Royal Infirmary & University of Edinburgh. Total outcomes: admission to 6 months. Largest multinational registry covering the full spectrum of ACS. ESC 2001. CURE. Study Design.

arvin
Télécharger la présentation

Keith A A Fox

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CURE and PCI-CURE Keith A A Fox Royal Infirmary & University of Edinburgh

  2. Total outcomes: admission to 6 months Largest multinational registry covering the full spectrum of ACS ESC 2001

  3. CURE Study Design • Randomized, double-blind trial: clopidogrel vs placebo in patients with ACS • All patients receive ASA (75-325 mg) • International trial (28 countries), 12,562 patients • Central randomization • Primary outcome: -CV death, MI, strokes

  4. CURE CURE Study 300mg loadingdose Clopidogrel75mg o.d.(~6,250 patients) Patients with Acute CoronarySyndrome Aspirin 75-325mg R 3 months > double-blind treatment < 12 months (UA or MI Without STelevation) Aspirin 75-325mg Placebo 1 tab o.d.(~6,250 patients) Day 1 loading dose 1 m. Visit 3 m. Visit 6 m. Visit 9 m. Visit 12 m.or Final Visit

  5. CURE Outcome Definitions CV Death: Excludes clear non-CV deaths MI: Two of three standard criteria: (Chest Pain, ECG, enzyme changes) Stroke: Neurological deficit  24 hrs (CT/MRI) Refractory Ischemia: Inhosp*: recurrent ischemia on max med Rx + ECG changes + intervention  1 day After discharge: Rehosp for UA with ECG changes Severe Ischemia*: Changes similar to RFA, but no intervention Recurrent Angina*: All other ischemic CP in hospital

  6. CURE Placebo Cumulative Hazard Rates Clopidogrel 0 3 6 9 12 No of Pts Months of Follow-up Plac Clop 6203 6259 5778 5864 4660 4780 3599 3640 2378 2414 Cumulative Hazard Rates for CV Death/MI/Stroke P = 0.00005 6303 6259

  7. CURE Cumulative Hazard Rates for CV Death/MI/Stroke up to 30 Days Placebo Cumulative Hazard Rates Clopidogrel P=0.003 0 10 20 30 Days of Follow-up No. Plac No. Clop 6303 6259 6097 6093 5994 6027 5954 5981

  8. CURE Very Early Events *p<0.05 **<0.01 *** <0.002

  9. CURE Events During Initial Hospitalization

  10. CURE: Who Benefits and When? • Similar benefits across all major treatment groups • On or off lipid lowering treatment, beta-blockers, heparin, ACE inhibitors • Irrespective of revascularization or not • RR 0.81 with and RR 0.78 without, both significant • Higher and lower risk groups show similar risk reduction • Curves separate early and remain separated • Primary outcome at 24hrs: • 143 vs 93 clopidogrel (RR 0.65 CI 0.50 – 0.85)

  11. CURE Life Threatening Bleed

  12. CURE Bleeds With CABG

  13. CURE: Magnitude of Benefit • Primary Outcome: • MI, stroke or CV death: 11.4% placebo, • 9.2%** clopidogrel (22 per 1000 absolute difference) • (Non-CV death 0.7 vs 0.7%) Treating 1000 patients for 9 months: prevents 28 vascular events with 6 individuals requiring transfusion TIMI bleeding criteria: 68 clopidogrel,73 placebo RR 0.94 (CI 0.68-1.30) GUSTO criteria: 78 clopidogrel, 70 placebo RR 1.11 (CI 0.81-1.55)

  14. PCI- Study Design CURE PCI-CURE N=2,658 patients undergoing PCI Pretreatment Open-label thienopyridine PLACEBO + ASA N = 1345 End of follow-up: 12 months 30 d. post PCI PCI Randomize Open-label thienopyridine CLOPIDOGREL + ASA N = 1313 Pretreatment

  15. PCI- Baseline Characteristics Placebo n=1272 Clopidogrel n=1254 Age (yrs) 61.4 61.6 Sex (%F) 30.1% 30.3% Diabetes 19.0% 19.0% Previous MI 26.0% 27.3% Prior PCI 13.8% 13.4% Prior CABG 13.0% 12.0% ST depression 43.2% 42.4%

  16. PCI- Overall Results: CV Death or MI 0.15 Placebo 0.10 Clopidogrel Cumulative Hazard Rate 0.05 P=0.002 0.0 0 10 40 100 100 200 200 300 300 400 400 A=median time to PCI B=30 days after PCI B Days following PCI A Lancet 2001: 358:527-33

  17. PCI- Events Before PCI Lancet 2001: 358:527-33

  18. PCI- Major Outcomes: From PCI to 30 days *Primary endpoint Lancet 2001: 358:527-33

  19. PCI- Placebo Clopidogrel + RRR P + ASA* ASA* Value N = 1345 N=1313 GP IIb/IIIa Inhibitior 26.6% 20.9% 81% 0.001 Need for second 17.1% 14.2% 18% 0.049 revascularization Other Outcomes Mehta SR et. al. Lancet 2001: 358:527-33

  20. PCI- Major Outcomes: Long Term Treatment Lancet 2001: 358:527-33

  21. Thrombolysis or Primary PCI Persistent ST elevation GP IIb/IIIa coronary angio High Risk recurrent ischaemia elevated troponin haemodynamic instability arrhythmia with ischaemia early post-MI unstable angina Stress Test Pre- or post- discharge Low Risk stable normal troponin Clinical Suspicion of ACS: Physical examination, ECG Blood samples No persistent STelevation Aspirin b-blocker “heparin” clopidogrel

More Related